Articles tagged with "upadacitinib"

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

October 14, 2021 • By Vanessa Caceres

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

October 14, 2021 • By Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD

FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

September 1, 2021 • By Keri Losavio

Health Canada Approves Upadacitinib to Treat Adults with PsA

July 6, 2021 • By Michele B. Kaufman, PharmD, BCGP

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

March 9, 2021 • By Vanessa Caceres

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

February 4, 2021 • By Michele B. Kaufman, PharmD, BCGP

Upadacitinib Safety Similar to Other Jakinibs for RA

November 16, 2020 • By Lisa Rapaport

RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement

October 1, 2020 • By Arthritis & Rheumatology

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution

September 30, 2020 • By Michele B. Kaufman, PharmD, BCGP

Janus kinase 1 protein.

Researchers Give Update on Janus Kinase (JAK) Inhibitors

May 15, 2020 • By Kimberly Retzlaff